Pfizer Touts Bosutinib Advantages, Debuts Hedgehog Inhibitor At ASH
By
Shirley Haley / Email the Author / Pharmaceutical Approvals Monthly December 2011, Vol. 16, No. 12
Pipeline Review / Word Count: 1996 / Article # 06111201023
Executive Summary
Among its presentations at the American Society of Hematology meeting, Pfizer debuted Hedgehog Smoothen inhibitor PF-04449913, showing off encouraging Phase I monotherapy data in highly refractory patients. The drug would pair nicely with late-stage bosutinib to hit chronic myelogenous leukemia in two ways: through stem cells and through mature cells, Pfizer’s Rothenberg said.
$85.00
Buy Now
For $85.00, purchase this 1996-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.